[1095] Bevacizumab (avastin) and albumin bound paclitaxel (abraxane) treatment in metastatic breast cancer.

Link JS, Waisman JR, Jacobs CI.. Breastlink Medical Group, Long Beach, CA; Long Beach Memorial Medical Center, Long Beach, CA

Background: Miller, et al demonstrated the combination of bevacizumab and paclitaxel has significant activity in metastatic breast cancer. Because paclitaxel albumin bound (PAB) has been shown to have less toxicity and a better tumor delivery, we combined it with bevacizumab (B) to treat women with metastatic breast cancer.
Material and Methods: 27 consecutive women with metastatic breast cancer were treated with a combination of PAB (80-125 mg/m² day 1, 8, 15 or 170-200 mg/m² every 14 days each on a 28 day cycle) and B (10mg/kg every 14 days). A minimum of two courses were given. Women had previously received a minimum of three chemotherapy regimens including anthracyclines (26/27) and taxanes (24/27). Patients were monitored for response using physical exam, tumor markers, and PET/CT fusion scanning. They also were monitored for toxicity.
Results: 27 women with heavily pretreated breast cancer received a minimum of two courses (two months) of treatment. Three patients had complete response (CR) (11%), 13 patients had a partial response (PR) (48%), with an overall response rate of 59%. Seven patients had stable disease and four patients progressed. Toxicity was acceptable. One patient was discontinued due to possible hemorrhage into a metastatic brain lesion. Two patients had elevation of liver transaminases; two patients had increase in blood pressure requiring antihypertensive medication; and one patient had a grade 3 rash/desquamation.
Conclusion and discussion: The combination of paclitaxel albumin bound and bevacizumab was very active in a population of heavily pre-treated women with metastatic breast cancer showing an objective clinical response rate of 59% (3 CR and 13 PR). Therapy was discontinued in one patient due to possible hemorrhage into a metastatic brain lesion.

Thursday, December 14, 2006 5:00 PM

Poster Session I: Treatment: Chemotherapy – New Drugs and Formulations (5:00 PM-7:00 PM)